1. 首页
  2. 抗体
  3. 正文

BD OptEIA- Human IFN- ELISA Set_BD Pharmingen

产品信息
抗原名称
IFN-γ
克隆号
(RUO)
BD化合物表
  • 描述
    数量/尺寸
    零件号
    EntrezGene ID
  • Capture Antibody Purified Anti-Human IFN-γ
    N/A
    51-26131E
    3458
  • Detection Antibody Biotin Anti-Human IFN-γ
    N/A
    51-26132E
    3458
  • Recombinant Human IFN-γ Lyophilized Standard
    N/A
    51-26136E
    3458
  • Streptavidin-horseradish peroxidase conjugate (SAv-HRP)
    N/A
    51-9002208
    N/A
应用
实验应用
ELISA (Routinely Tested)
反应种属
Human (QC Testing)
目标/特异性
IFN-γ
文献
文献
研发参考(6) 1. Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.. J Immunol. 2000; 165(5):2903-2910. (Biology). 2. Salih HR, et al. Constitutive Expression of Functional 4-1 BB (CD 137) Ligand on Carcinoma Cells. J Immunol. 2000; 165(5):2903–2910. (Biology). 3. Sester U, Sester M, Hauk M, Kaul H, Köhler H, Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients.. Nephrol Dial Transplant. 2000; 15(8):1217-1223. (Biology). 4. Sester U, et al. T-cell Activation Follows Th1 Rather than Th2 Pattern in Haemodialysis Patients. Nephrology Dialysis Transplantation. 2000; 15:1217–1223. (Biology). 5. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.. Nat Med. 2001; 7(3):297-303. (Biology). 6. Wolfers J, et al. Tumor-Derived Exosomes are a Source of Shared Tumor Rejection Antigens for CTL Cross-Priming. Nature Medicine. 2001; 9(3):297-303. (Biology).

参考图片

This standard curve is for demonstration only. A standard curve must be run with each assay. Typical Standard Curve and 20-plate yield were obtained in the BD Biosciences Pharmingen laboratory, using the recommended procedure and manual plate washing.

文档下载: W 导出为BD OptEIA- Human IFN- ELISA Set_BD Pharmingen.doc文档

本文来自投稿,不代表本人立场,如若转载,请注明出处:http://www.iamyjet.com/kangti/9817.html

(function(){ var src = (document.location.protocol == "http:") ? "http://js.passport.qihucdn.com/11.0.1.js?1d7dde81dc0903e04d3ac0b9599444f6":"https://jspassport.ssl.qhimg.com/11.0.1.js?1d7dde81dc0903e04d3ac0b9599444f6"; document.write('<\/mip-script>'); })(); (function(){ var bp = document.createElement('script'); var curProtocol = window.location.protocol.split(':')[0]; if (curProtocol === 'https') { bp.src = 'https://zz.bdstatic.com/linksubmit/push.js'; } else { bp.src = 'http://push.zhanzhang.baidu.com/push.js'; } var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(bp, s); })();